Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of DS-1001b in Patients with IDH1 Mutated Gliomas

Next Previous
Trial Profile

A Phase 1 Study of DS-1001b in Patients with IDH1 Mutated Gliomas

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Safusidenib (Primary)
  • Indications Glioma
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 14 Feb 2023 Results assessing the safety, pharmacokinetics, pharmacodynamics, and efficacy of DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas published in the Neuro-Oncology
    • 12 Mar 2021 Planned End Date changed from 1 Mar 2022 to 1 Mar 2026.
    • 07 Sep 2020 According to an AnHeart Therapeutics media release, it has entered into license agreements with Daiichi Sankyo Company, to acquire rights to DS-1001 novel clinical stage oncology candidates.AnHeart will develop this compound for glioma and potentially other indications including acute myeloid leukemia (AML) and cholangiocarcinoma globally, except in Japan where Daiichi Sankyo will retain exclusive rights.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top